Gothenburg, Sweden – 18.08. 2009.
Denator AB confirmed today the expansion of the company's operations team through the appointment of David Zeeberg to head the company’s product development and production efforts.
David joins Denator from Semcon Caran where he worked for 13 years. During this time, David worked as Development Manager and also Department Manager of the Total Design Office focusing on customer projects both in product-development and production-equipment.
David said: "Denator has an enviable reputation for technical expertise and innovation for proteomics workflow. Denator’s product portfolio is in a very exciting stage of evolution and it is fantastic to become part of the team at such an active time. Part of the attraction of this new role is the ability to input from the conceptual phase of product development and supply chain, right through to personal interaction with the end user.
Olof Sköld, CEO at Denator, stated: "The extensive experience and proven abilities that David possesses will significantly strengthen our operation’s team. He will undoubtedly play a key role in the further development of Denator’s product portfolio. This appointment signifies our determination to increase our footprint in the proteomics market and fully exploit the commercial potential of our excellent portfolio."
Denator’s first commercial system for tissue stabilization was launched at the HUPO meeting in Amsterdam in August, 2008.
About Denator
Denator intends to become the leading supplier of products that stabilize biological tissues and fluids from the moment of sampling. Stabilization and standardization of sampling processes upstream significantly enhances the quality of data obtained from analytical techniques used downstream. In proteomic and peptidomic investigations, enhanced data quality increases the reliability of data interpretation and can reveal novel proteins and peptides that would be lost or undetectable when using conventional preparation techniques. Based upon the company’s proprietary heat-inactivation technology platform, Denator is developing solutions that enable scientists to stop sample degradation instantly and maintain the stability of sample components throughout the analytical workflow. Established in 2004, Denator is headquartered at the Biotech Center in Gothenburg, Sweden. For more information visit: www.denator.com or contact
Charlotte Emlind Vahul
Business Development
Denator AB
E-mail: charlotte @denator.com
Tel.: +46 31 41 28 41
Fax.: +46 31 41 28 40
David joins Denator from Semcon Caran where he worked for 13 years. During this time, David worked as Development Manager and also Department Manager of the Total Design Office focusing on customer projects both in product-development and production-equipment.
David said: "Denator has an enviable reputation for technical expertise and innovation for proteomics workflow. Denator’s product portfolio is in a very exciting stage of evolution and it is fantastic to become part of the team at such an active time. Part of the attraction of this new role is the ability to input from the conceptual phase of product development and supply chain, right through to personal interaction with the end user.
Olof Sköld, CEO at Denator, stated: "The extensive experience and proven abilities that David possesses will significantly strengthen our operation’s team. He will undoubtedly play a key role in the further development of Denator’s product portfolio. This appointment signifies our determination to increase our footprint in the proteomics market and fully exploit the commercial potential of our excellent portfolio."
Denator’s first commercial system for tissue stabilization was launched at the HUPO meeting in Amsterdam in August, 2008.
About Denator
Denator intends to become the leading supplier of products that stabilize biological tissues and fluids from the moment of sampling. Stabilization and standardization of sampling processes upstream significantly enhances the quality of data obtained from analytical techniques used downstream. In proteomic and peptidomic investigations, enhanced data quality increases the reliability of data interpretation and can reveal novel proteins and peptides that would be lost or undetectable when using conventional preparation techniques. Based upon the company’s proprietary heat-inactivation technology platform, Denator is developing solutions that enable scientists to stop sample degradation instantly and maintain the stability of sample components throughout the analytical workflow. Established in 2004, Denator is headquartered at the Biotech Center in Gothenburg, Sweden. For more information visit: www.denator.com or contact
Charlotte Emlind Vahul
Business Development
Denator AB
E-mail: charlotte @denator.com
Tel.: +46 31 41 28 41
Fax.: +46 31 41 28 40
